JBC Transcription and Nuclear Factor Monoclonals

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M604332200 on July 7, 2006

J. Biol. Chem., Vol. 281, Issue 35, 25803-25812, September 1, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/35/25803    most recent
M604332200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levin, M. H.
Right arrow Articles by Verkman, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levin, M. H.
Right arrow Articles by Verkman, A. S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Hypertonic Saline Therapy in Cystic Fibrosis

EVIDENCE AGAINST THE PROPOSED MECHANISM INVOLVING AQUAPORINS*

Marc H. Levin{ddagger}**1, Shannon Sullivan{ddagger}, Dennis Nielson, Baoxue Yang{ddagger}, Walter E. Finkbeiner||, and A. S. Verkman{ddagger}§**2

From the Departments of {ddagger}Medicine, §Physiology, Pediatrics, and ||Pathology, and **Graduate Group in Biophysics, University of California, San Francisco, California 94143-0521

Received for publication, May 5, 2006 , and in revised form, July 5, 2006.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Recent data indicate the clinical benefit of nebulized hypertonic saline in cystic fibrosis lung disease, with a proposed mechanism involving sustained increase in airway surface liquid volume. To account for the paradoxical observation that amiloride suppresses the beneficial effect of hypertonic saline, it has been previously concluded (Donaldson, S. H., Bennett, W. D., Zeman, K. L., Knowles, M. R., Tarran, R., and Boucher, R. C. (2006) N. Engl. J. Med. 354, 241-250) that amiloride-inhibitable aquaporin (AQP) water channels in airway epithelia modulate airway surface liquid volume. Here, we have characterized water permeability and amiloride effects in well differentiated, primary cultures of human airway epithelial cells, stably transfected Fisher rat thyroid epithelial cells expressing individual airway/lung AQPs, and perfused mouse lung. We found high transepithelial water permeability (Pf, 54 ± 5 µm/s) in airway epithelial cells that was weakly temperature-dependent and inhibited by >90% by reduced pH in the basal membrane-facing solution. Reverse transcription-PCR and immunofluorescence suggested the involvement of AQPs 3, 4, and 5 in high airway water permeability. Experiments using several sensitive measurement methods indicated that amiloride does not inhibit water permeability in non-cystic fibrosis (non-CF) or CF airway epithelia, AQP-transfected Fisher rat thyroid cells, or intact lung. Our data provide evidence against the mechanism proposed by Donaldson et al. to account for the effects of amiloride and hypertonic saline in CF lung disease, indicating the need to identify alternate mechanisms.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Cystic fibrosis (CF)3 is a relatively common hereditary disease in Caucasians caused by mutations in the CF transmembrane conductance regulator (CFTR) chloride channel. Morbidity and mortality in CF result primarily from chronic airway infection, which results in progressive deterioration of lung function.

Two recent clinical studies have demonstrated short and long term benefits of nebulized hypertonic saline in improving lung function in CF (1, 2). Prior clinical studies also support the efficacy of various inhaled hyperosmolar agents in CF (3-6). The recent study by Donaldson et al. (1) concludes that hypertonic saline produces sustained elevation in airway surface liquid (ASL) volume, which improves mucociliary clearance in the airways. However, a paradoxical effect was found when amiloride was administered together with hypertonic saline. Rather than improving lung function because of its inhibitory effect on ENaC and consequent prevention of ASL absorption, amiloride negated the beneficial effect of hypertonic saline. To account for these findings, Donaldson et al. (1) postulated the involvement of airway AQPs in establishing ASL volume (Fig. 1) and reported strong amiloride inhibition of osmotic water permeability in airway epithelial cells. In their model, ENaC hyperactivity dehydrates the ASL in CF airways (Fig. 1, left panel), and hypertonic saline restores ASL volume (middle panel). If amiloride acts only on ENaC, then amiloride is predicted to increase ASL volume (Fig. 1, right, top panel). To account for the clinical data, they hypothesize that amiloride inhibits airway AQPs, which prevents water from entering the airways (Fig. 1, right, bottom panel).

The proposed involvement of AQPs in ASL regulation is surprising, as is the inhibition of AQP water permeability by amiloride. Osmotically induced water transport across airways has been shown to be high and likely AQP-dependent in microperfused small airways (7) and later in cultured human tracheal epithelial cells (8) and in spheroids composed of airway epithelial cell monolayers (9). Despite this, the reduction of airway epithelial water permeability by deletion of the various lung/airway aquaporins (AQPs 1, 3, 4 and 5) in transgenic mice did not affect ASL volume or ionic composition (10). Inhibition of AQP water permeability by amiloride is surprising, because amiloride has no aquaretic effect at concentrations that inhibit ENaC in the renal distal tubule.

Here, we tested the hypothesis of Donaldson et al. (1) by characterizing water permeability and amiloride effects in human bronchial epithelial cell cultures, stably transfected epithelial cells expressing airway/lung AQPs, and intact lung using a variety of biophysical methods to quantify water transport. Water permeabilities of airway cells and intact lung surface were found to be high and AQP-dependent, although amiloride did not inhibit water permeability nor did it inhibit water permeability of the individual AQPs. These findings have important implications for understanding the benefit of hypertonic saline in CF and for future development of related strategies for the therapy of CF lung disease.


Figure 1
View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 1.
Proposed mechanism of hypertonic saline and amiloride effects on airway surface liquid (ASL) in cystic fibrosis. In CF, periciliary fluid is depleted because of impaired Cl- secretion through CFTR and increased Na+ absorption through ENaC (left panel). Hypertonic saline is proposed to increase ASL volume (middle panel) via AQP-mediated and/or transmembrane water movement (blue arrows). By inhibition of ENaC, amiloride is postulated to increase ASL volume by blocking Na+ and fluid absorption (right, top panel). Amiloride inhibition of AQP water channels was proposed as a mechanism to account for the amiloride effect of negating the beneficial clinical effects of hypertonic saline (right, bottom panel).

 

   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture—Surface bronchial epithelial cells were obtained from non-CF human lung specimens that were not suitable for lung transplantation. CF bronchial epithelial cells were obtained from patients at the time of transplantation. The cells were dissociated by enzymatic digestion, as described previously (11). Isolated cells were suspended in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F-12 medium containing 5% fetal calf serum (Hyclone, Logan, UT), gentamicin (50 µg/ml), penicillin (100 units/ml), streptomycin (1 mg/ml), and fungizone (2.5 µg/ml) and seeded as passage 0 (P0) cultures at a density of 106 cells/cm2 onto 12-mm Transwell polycarbonate inserts (0.4 µm pore size; Costar, Corning, NY) overlaid with a thin coat (15 µg/cm2) of human placental collagen (Sigma-Aldrich). The next day, the cells were rinsed with PBS, and the medium was replaced with air-liquid interface medium (12) containing gentamicin, penicillin, and streptomycin at the concentrations given above. The medium was changed daily. When the cell sheets became confluent and actively absorbed mucosal fluid, as indicated by the loss of apical fluid in the central portion of the insert (generally 3-5 days), the mucosal surface was rinsed with PBS, and medium was added only to the basal side of the insert.

For some experiments, bronchial epithelial cells (non-CF and CF) were obtained after expansion in human placental collagen-coated tissue culture flasks. After 80-90% confluence, cells were released using 0.05% trypsin and 0.2% EDTA in 0.9% NaCl at 37 °C. The trypsin was neutralized with Dulbecco's modified Eagle's medium/Ham's F-12 medium containing 20% fetal calf serum, and propagated cells were resuspended in plating medium and seeded onto cell culture inserts as described above but designated as passage 1 (P1) cultures. By day 15 after seeding, both P0 and P1 cultures formed tight layers with transepithelial resistance of 1-2 k{Omega}·cm2, at which time they were used for experiments. Cultures were confirmed to express cAMP-activated CFTR by measurement of short circuit current, as reported previously (13). Protocols were approved by the University of California, San Francisco Committee on Human Research.

Fisher rat thyroid (FRT) epithelial cells stably transfected with either control plasmid (encoding yellow fluorescent protein) or with plasmids encoding AQP1, AQP3, or AQP4 (14) were grown in F-12/Coombs medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Hyclone), penicillin G (100 units/ml), streptomycin (100 µg/ml), and the appropriate antibiotic selection markers. For dye dilution experiments, FRT cells were plated onto uncoated Transwell inserts and used for flux measurements at resistances of 2-5 k{Omega}·cm2.

Transepithelial Water Permeability—Osmotic water permeabilities across human bronchial epithelial (HBE) and FRT cell layers were determined using a dye dilution method, as depicted in Fig. 2A. The dilution of a cell-impermeant, photostable, inert dye (Texas RedTM-dextran, 10 kDa; Molecular Probes, Eugene, OR) was used as a measure of transcellular osmotic water flux. The basal surface of cells on the porous filter was bathed in 1 ml of isosmolar PBS. The apical surface was bathed in 200 µl of hyperosmolar PBS (PBS + 300 mM D-mannitol) containing 0.25 mg/ml Texas Red-dextran. In some experiments, 100-500 µM amiloride (Sigma-Aldrich), dissolved freshly from powder, was added to the apical buffer, as done by Donaldson et al. (1), or to both the apical and basal bathing buffers. Cultures were placed in a 5% CO2 tissue culture incubator (at 27 or 37 °C), and 5 µl samples of dye-containing apical fluid were collected at specified times. The samples were diluted in 2 ml of PBS, and fluorescence was measured by cuvette fluorimetry (Fluoro Max-3; Horiba, Tokyo, Japan). In some experiments, the osmotic gradient was reversed by the addition of mannitol to the basal rather than the dye-containing apical solution. In other experiments, the pH of either the basal or apical solutions was adjusted to 5.0 using buffers containing 137.6 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 6 mM D-glucose, and 10 mM HEPES (for pH 7.4) or MES (for pH 5.0). In some experiments, HgCl2 (0.2 or 1 mM) was added to the apical and basolateral solutions 5 min prior to the osmotic gradient.

For computation of transepithelial osmotic water permeability coefficients (Pf, in cm/s), the time course of fluorescence in response to solution osmolarity changes, F(t), was fitted to a single exponential time constant, F(t)/Fo = B + A·e-t/{tau}, where Fo is initial fluorescence, A is amplitude, and {tau} is the exponential time constant. Because of dye binding to cells and/or the support, data used for exponential regression was collected at 5 min and later after establishing the osmotic gradient. Water flux was computed as the rate of dye dilution by dV(0)/dt = Vo·A/{tau}, which follows from the relation: F(t)/Fo = Vo/(Vo + V(t)). Vo is the initial volume of dye-containing apical buffer (0.2 cm3), and V(t) is the apical solution volume at time t. From these equations, Pf was computed as dV(0)/dt = Pf·S·vw·({Phi}1 - {Phi}2), where S is the tissue surface area assuming a smooth surface (1.13 cm2), vw is the partial molar volume of water (18 cm3/mol), and ({Phi}1 - {Phi}2) is the transepithelial osmotic gradient (3 x 10-4 mol/cm3).

Plasma Membrane Water Permeability—Plasma membrane osmotic water permeability was measured using a calceinquenching method (shown in Fig. 3A) that has been applied previously to in vitro and in vivo cell systems (15, 16). Cells were loaded with calcein by incubation with PBS containing 10 µM calcein-AM (Molecular Probes) for 30 min at 37 °C. HBE cultures grown on collagen-coated supports were studied by cutting the flat supports from the plastic inserts and mounting them in a custom-built perfusion chamber with support bottoms pressed against a coverslip and apical cell surfaces exposed to the perfusate. FRT cells grown on glass coverslips were inserted in a similar perfusion chamber but with cells facing upwards. Solutions were exchanged between PBS (290 mOsm) and hyperosmolar PBS (590 mOsm, PBS with added D-mannitol) using a gravity pinch valve system (ALA Scientific Instruments, Westbury, NY). Perfusates contained either Me2SO vehicle (0.1%) or amiloride (500 µM) added from a 1000x Me2SO stock solution. Fluorescence was excited using an X-cite 120 mercury lamp (EXFO Life Sciences, Ontario, Canada) and focused through an inverted epifluorescence microscope through a long working distance 25x air objective (numerical aperture 0.35, Leitz). Excitation and emission light was filtered using a custom cube (Chroma, Rockingham, VT), and fluorescence was collected using a 14-dynode photomultiplier and then amplified, digitized, and recorded using custom software (written in LabView, National Instruments, Austin, TX).

To compute plasma membrane Pf, relative fluorescence (F(t)/Fo) was fitted to a single exponential function (as above) for FRT cell studies or a biexponential function (F(t)/Fo = A·e-t/{tau}1 + B·e-t/{tau}2 + C) for HBE studies. Plasma membrane Pf was computed as described above, where surface area S was taken as the apical surface area of the cell monolayer, assuming a flat, smooth surface. The time-varying cell layer height, h(t), was related to normalized amplitudes according to the predicted 50% final decrease from initial height (ho) under hypertonic conditions. For FRT and HBE cells, ho was taken as 5 and 20 µm, respectively. Pf was then computed from dh(0)/dt = Pf·vw·({Phi}1 - {Phi}2).

Airspace-Capillary Water Permeability in Intact Lung— Wild-type and AQP5-deficient mice in a CD1 genetic background (age 8-14 weeks) (17) were sacrificed using an overdose of 2,2,2-tribromoethanol (avertin, Sigma-Aldrich) intraperitoneally. Protocols were approved by the University of California, San Francisco Committee on Animal Research. The trachea was transected and cannulated, the pulmonary artery was cannulated, and the heart and lungs were moved en bloc to a perfusion chamber as described previously (18). After ensuring that no air leaks were present, 0.5 ml of fluorescein isothiocyanate-dextran solution (10 kDa, 0.5 mg/ml in PBS; Sigma-Aldrich), with or without freshly dissolved amiloride (500 µM), was instilled into the tracheal catheter. The pulmonary artery was perfused at constant pressure (~60 cm H2O) with PBS, with or without 500 µM amiloride, for at least 5 min before measurements. The pleural surface was washed continuously with PBS, and perfusate and wash effluent were continuously withdrawn from the chamber by suction (perfusate flow 5 ml/min). The time course of fluorescence intensity from a 3-5-mm spot on the lung pleural surface, in a similar location for all samples, was continuously monitored while perfusate fluid was exchanged between isosmolar and hyperosmolar PBS (PBS + 300 mM D-mannitol) using the microscope setup, detection system, and gravity pinch valve system described above.

Histology and Immunocytochemistry—Paraffin sections of P0 HBE cell culture inserts and fixed human trachea were prepared. For paraffin sections, inserts were fixed for at least 30 min in buffered formalin (10%) and stored in 0.1 M phosphate buffer (pH 7.4). Standard tissue dehydration and paraffin infiltration was performed in a Tissue-Tek VIP processor (Sakura Finetek, Torrance, CA). Sections were cut at 4 µm on a rotary microtome and stained with hematoxylin and eosin. Specimens were viewed and photographed on an Olympus light microscope (Olympus America, Inc., Melville, NY) equipped with a digital imaging system (QImaging, Burnaby, Canada). Immunostaining was done by standard procedures using polyclonal antibodies for AQP3, AQP4, and AQP5 (Chemicon, Temecula, CA) incubated for 2 h and Cy3-conjugated goat anti-mouse IgG (1:200; Sigma-Aldrich) incubated for 30 min.

Reverse Transcription (RT)-PCR—Total RNA from HBE cells scraped freshly from P0 culture inserts was isolated by homogenization in TRIzol reagent (Invitrogen), and mRNA was extracted using the Oligotex mRNA midi kit (Qiagen, Valencia, CA). cDNA was reverse transcribed from mRNA with oligo(dT) (SuperScript II preamplification kit, Invitrogen). Primers were designed to amplify 300-350 base pair fragments of cDNAs encoding human beta-actin (sense, 5'-GCATGGAGTCCTGTGGCATCC-3'; antisense, 5'-CATTTGCGGTGGACGATGGAC-3'), AQP1 (sense, 5'-GCCATCG GCCTCTCTGTAGCC-3'; antisense 5'-CTATTTGGGCTTCATCTGCAC-3'), AQP2 (sense, 5'-ACCTCCTTGGGATCCATTACA-3'; antisense, 5'-TCAGGCCTTGGTACCCCGTGG-3'), AQP3 (sense, 5'-CTGGTGGTCCTGGTCATTGGC-3'; antisense, 5'-CTGCTCCTTGTGCTTCACATG-3'), AQP4 (sense, 5'-GGACCTGCAGTTATCATGGGA-3'; antisense, 5'-CAATACCTCTCCAGATTGTGC-3'), AQP5 (sense, 5'-CTGTCCATTGGCCTGTCTGTC-3', antisense, 5'-GCGGGTGGTCAGCTCCATGGT-3'), AQP6 (sense, 5'-CTGGGCCACCTCATTGGGATC-3'; antisense, 5'-TCACACACTCTCCATCTCCAC-3), AQP7 (sense, 5'-CAGGTCTTCAGCAATGGGGAG-3'; antisense, 5'-CTCTAGGGCCATGGATTCATG-3'), AQP8 (sense, 5'-GTGGCAGAGATCATCCTGACG-3'; antisense, 5'-TTCAGGATGAGGCGGGTCTTC-3'), and AQP9 (sense, 5'-GACTCCAGAAACTTGGGAGCC-3'; antisense, 5'-TTGTCCTCAGATTGTTCTGCC-3'). RT-PCR (for stained agarose gels) was performed with the TaqDNA polymerase kit (Invitrogen), and PCR products were electrophoresed on a 1.2% agarose gel.

Fluorescence-based real-time RT-PCR was done to compare relative AQP3, AQP4, and AQP5 mRNA expression in non-CF versus CF cells using the LightCyclerTM and with the LightCycler FastStart DNA MasterPLUS SYBR Green I kit (Roche Diagnostics) according to the manufacturer's instructions. Surface epithelial cells were dissociated from human bronchi, quick-frozen, and stored at -80 °C until thawed for RNA isolation. PCR primers were as described above. Results were reported as a normalized, calibrated ratio with all samples normalized to beta-actin. Concentration ratios for each CF and non-CF sample were calibrated to calibrator samples (pooled cDNA from non-CF subjects), with the results reported as a normalized ratio with the calibrator sample as the denominator as follows: relative mRNA level = ratio of sample (target/reference)/ratio of calibrator (target/reference).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Water transport in airway surface epithelium was studied using well differentiated HBE cell cultures. Transepithelial osmotic water permeability was measured using a dye dilution method that assays water flux across tight epithelia cultured on porous filters (Fig. 2A). The fluorescence of an apical solution volume marker provided a quantitative readout of osmotically driven water transport across the cell layer. An induced osmotic gradient caused transepithelial water movement from which osmotic water permeability (Pf) was deduced. The P0 non-CF cultures were first characterized. Fig. 2B (top) shows fluorescence dilution at 37 °C, in which a 300 mM gradient of D-mannitol induced osmotic water flux into the apical, dye-containing solution. Data in the absence versus the presence of amiloride (500 µM) were compared. Fig. 2C summarizes transepithelial Pf values. There was no significant difference in Pf upon exposure of P0 HBE cultures to high dose amiloride (control versus amiloride, 54 ± 5 versus 52 ± 7 µm/s). Lower concentrations of amiloride (100 and 250 µM) also did not change Pf (not shown).

When the direction of the osmotic gradient was reversed by the addition of mannitol to the basal bathing solution, the fluorescent volume marker became concentrated over time (Fig. 2B, middle). The deduced transepithelial Pf (46 ± 15 µm/s) did not differ significantly from that in control studies (mannitol in apical solution), indicating symmetrical water transport. To investigate the involvement of AQPs in HBE water permeability, experiments were done at reduced temperature (27 °C) and with reduced pH in the apical or basal bathing solutions (Fig. 2C, bottom). Pf at 27 °C (47 ± 9 µm/s) was similar to that at 37 °C, indicating a low Arrhenius activation energy, as expected for AQP-facilitated water transport. Reducing apical solution pH to 5 did not change Pf significantly, whereas a basolateral solution pH of 5 decreased Pf by >90%, providing functional evidence for the involvement of basolateral membrane AQP3 in water permeability; the water permeability of AQP3 is inhibited at low pH, whereas that of other AQPs is not (19).


Figure 2
View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 2.
Transepithelial water permeability of human bronchial cell cultures. Water permeability across HBE cell layers measured by a dye dilution fluorescence method. A, schematic of osmotically induced transcellular water flux across porous Transwell membranes. Water movement from basal to apical solutions reduces the concentration of an inert volume marker in the apical solution. B, time course of osmotic water movement across P0 HBE cell cultures, with apical solution fluorescence normalized as F/Fo, and single exponential fits shown as solid lines (see "Experimental Procedures"). Top, comparison of control cultures (open circles) with cultures exposed to 500 µM amiloride at their apical surface (closed circles). Measurements performed at 37 °C (7 cultures/group ± S.E.). Middle, time course of apical solution fluorescence upon inclusion of 300 mM D-mannitol in basal (rather than apical) surface-facing buffer (37 °C, four cultures ± S.E.). Bottom, comparison of control cultures (open circles) with cultures exposed to low pH at their apical (open triangles) or basolateral (open squares) surfaces (27 °C, four cultures ± S.E.). C, summary of Pf for experiments in B. *, p < 0.05. D, summary of Pf for experiments done on P1 non-CF and CF HBE cells, in the absence and presence of 500 µM apical amiloride (37 °C, 4 cultures for each non-CF group and five cultures for each CF group ± S.E.). E, time course of osmotic water movement across P0 HBE cells, comparing control cultures (open circles) with cultures exposed to 500 µM amiloride at both apical and basolateral surfaces (closed circles). Data expressed as absolute fluorescence in arbitrary units (four cultures/group ± S.E.).

 
Non-CF and CF P1 cell cultures were also studied to mimic the culture conditions employed by Donaldson et al. (1). As summarized in Fig. 2D, P1 cultures had ~50% lower water permeability than P0 cultures but without significant differences comparing non-CF versus CF cultures or control cultures versus cultures exposed apically to 500 µM amiloride (or to 100 µM amiloride, not shown). Finally, as an additional attempt to look for amiloride-sensitive water transport, water permeability was measured in P0 non-CF cultures in the presence of both apically and basolaterally added amiloride (500 µM). As seen from the raw fluorescence data in Fig. 2E, osmotic water flux was not inhibited by high-dose amiloride, indicating the lack of amiloride inhibition of apical or basolateral AQPs.


Figure 3
View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 3.
Plasma membrane water permeability of human bronchial cell cultures. Water permeability measured by a calcein fluorescence-quenching method. A, schematic of cell volume-dependent calcein quenching, where apical plasma membrane exposure to hypertonic buffer induces cell shrinking, reducing cytoplasmic calcein fluorescence because of quenching by anionic cytoplasmic proteins. B, representative time courses of calcein fluorescence in HBE cells in response to hyperosmolar challenge followed by return to isosmolar solution, in the absence (top) or presence (bottom) of 500 µM amiloride. Double exponential fits used for Pf determination are overlaid (see "Experimental Procedures"). C, summary of calculated Pf (3-6 curves averaged for individual cultures, three cultures/condition ± S.E.). Differences were not significant.

 
Plasma membrane water permeability in P0 HBE cultures was determined using a calcein-quenching method, which is based on rapid changes in cytoplasmic calcein fluorescence in response to changes in the concentration of cytoplasmic anionic proteins and hence to changes in cell volume (Fig. 3A) (15). Supports with calcein-loaded HBE cells were mounted in a perfusion chamber for continuous measurement of cytoplasmic calcein fluorescence. Switching between isosmolar and hyperosmolar perfusates produced reversible changes in fluorescence with biexponential kinetics (Fig. 3B), probably reflecting the heterogeneous distribution of AQPs and the complicated geometry of bronchial epithelia. Pf was quantified from the initial kinetics of fluorescence change in response to osmotic gradients as described under "Experimental Procedures." As summarized in Fig. 3C, the plasma membrane Pf was not significantly affected by inclusion of 500 µM amiloride in the perfusates.

AQP expression was characterized in P0 HBE cells. Hematoxylin and eosin-stained transverse paraffin sections confirmed the differentiation of 2-week-old cultures into a ~20-µm thick pseudostratified epithelium with numerous cilia (Fig. 4A). Cultures were scraped for RT-PCR analysis, which detected mRNA for several AQPs (Fig. 4B). Transcripts of AQP3, AQP4, and AQP5 were found in highest abundance, consistent with previous studies (see "Discussion"). Lesser but non-zero expression of AQP1, AQP6, and AQP7 mRNA was detected. Quantitative real-time RT-PCR was done to compare expression of the principal AQPs in P0 HBE cultures from non-CF versus CF airways. As summarized in Fig. 4C, no significant differences were found in AQP transcript expression in non-CF versus CF cells. Immunofluorescence done on paraffin sections of HBE cultures and intact human bronchus demonstrated AQP3 and AQP4 protein expression on basolateral membranes, whereas AQP5 protein expression was not detected. Positive control staining of kidney for AQP3 and AQP4 is shown and of salivary gland for AQP5.

We next investigated the possible effects of amiloride on the major lung AQPs, including AQP1 (expressed in microvascular endothelia), using AQP-transfected epithelial cells and intact mouse lung. Transepithelial and plasma membrane water permeabilities were measured in FRT cells expressing either yellow fluorescent protein (control), AQP1, AQP3, or AQP4. Transepithelial water permeability of FRT cell lines grown on Transwell supports was measured after the cultures formed electrically tight monolayers. Water permeabilities of AQP-expressing FRT cells were greater than that in control cells and not sensitive to amiloride (Fig. 5A, top). Fig. 5A (bottom) summarizes transepithelial Pf values. Plasma membrane water permeability was measured on the FRT cells, with calcein fluorescence curves fitted to single exponential functions (representative traces for FRT-AQP3 and FRT-AQP4 cells shown in Fig. 5B, top). In agreement with the measurements of transepithelial water permeability, plasma membrane Pf was increased with AQP expression and not sensitive to amiloride (Fig. 5B, bottom).

Last, the effect of amiloride was investigated in intact, perfused mouse lung using a pleural surface method to measure airspace-capillary osmotic water permeability (18). The airspace compartment was filled with isotonic fluid containing fluorescein isothiocyanate-dextran as a volume marker. The kinetics of pleural surface fluorescein isothiocyanate-dextran fluorescence was measured in response to changes in osmolality of the pulmonary artery perfusate. There was rapid osmotic equilibration across the airspace-capillary barrier, which was not affected by the inclusion of 500 µM amiloride in the airway instillate and pulmonary artery perfusate (Fig. 6A, top). In agreement with previous results (20), osmotic equilibration was ~10-fold slowed in lungs of AQP5-deficient mice (Fig. 6A, bottom), indicating the involvement of AQP5 in airspace-capillary osmotic water transport. The rates of osmotic water equilibration in lungs from wild-type mice (with and without amiloride) are summarized in Fig. 6B.


Figure 4
View larger version (66K):
[in this window]
[in a new window]
  		FIGURE 4.
Aquaporin expression in human airway epithelial cells. A, histology of well differentiated HBE cells. Hematoxylin and eosin-stained section cut from non-CF culture embedded in paraffin. Scale bar, 20 µm. B, AQP transcript expression in HBE cultures. Top, RT-PCR analysis of HBE cultures. Bottom, positive control taken from cDNA pooled from human brain, kidney, and lung. C, quantitation of relative AQP3, AQP4, and AQP5 mRNA expression in P0 CF versus non-CF HBE cells by fluorescence-based RT-PCR (see "Experimental Procedures"; two CF and three non-CF subject isolates analyzed ± S.E.). D, AQP3, AQP4, and AQP5 immunostaining of paraffin sections of human bronchus tissue (top panels), HBE culture (middle panels), and positive controls (mouse renal cortex, bottom left; renal medulla, bottom middle; salivary gland, bottom right). Arrows denote apical side and arrowheads denote basal side. Scale bar, 50 µm. cont, control.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The primary purpose of this study was to investigate a proposed AQP-dependent mechanism to account for the clinical effects of nebulized hypertonic saline (HS) and amiloride on lung function in CF. The validity of the proposed mechanism of clinical benefit involving amiloride-sensitive airway AQPs has important implications regarding the use of HS versus non-salt hyperosmolar agents in CF therapy, as well as in the proposed use of amiloride-type ENaC inhibitors in preventing ASL dehydration.

HS is being used increasingly as a chronic therapy in CF, particularly following the recent publication of two clinical trials in the New England Journal of Medicine demonstrating clinical benefit (1, 2). The larger of the two studies reported that 4 ml of 7% HS nebulized twice daily for 48 weeks decreased exacerbation rate by 56% in CF subjects (2). Exacerbations were defined by the need for intravenous antibiotics or using a symptom score involving increased sputum production, lethargy, dyspnea, and fever. In previous smaller studies of CF subjects, a single nebulized dose of 6-7% HS increased mucociliary clearance at 60 and 90 min, as measured by radionucleotide imaging (3, 5). Increased mucociliary clearance was dose-dependent up to 12% HS in 10 adults treated with a single dose and tested at 90 min (4). In a 2-week study in 52 CF subjects, 10 ml of 6% HS improved lung function as measured by a 12% increase in forced expiratory volume in 1 s (FEV1) (6). HS has also been shown to increase mucociliary clearance in healthy subjects and in subjects with asthma or chronic obstructive lung disease (21, 22).

Various non-salt hyperosmolar agents have been posited to improve mucus clearance in CF and other chronic inflammatory lung diseases. The best-studied non-salt hyperosmolar agent is mannitol. In 12 CF subjects, single dose administration of 300 mg of mannitol as a dry powder improved bronchial mucus clearance at 60 min, although there was a small decline in FEV1 immediately after inhalation that was unresponsive to bronchodilator premedication (5). The same dose of mannitol improved mucus clearance 2-fold in healthy, asthmatic, and bronchiectatic subjects (21, 23). A 12-day trial of 400 mg of mannitol daily in nine non-CF bronchiectatic subjects gave no change in FEV1 but improved various sputum characteristics, such as surface tension and spinnability (24). Another inhaled hyperosmolar agent, xylitol, reduced ASL salt concentration in CF and non-CF airway epithelia in vitro (25). Pretreatment of human airway explants for 1 h with 60-80 mg/ml xylitol reduced binding of a Burkholderia cepacia isolate (26).


Figure 5
View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 5.
Transepithelial and membrane water permeabilities in AQP-transfected FRT cell cultures. A, transepithelial osmotic water permeability of transfected FRT cells measured by dye-dilution. Top, averaged time courses of osmotic water movement in FRT cell cultures transfected with yellow fluorescent protein (YFP) (circles), AQP1 (squares), AQP3 (diamonds), and AQP4 (triangles), with apical solution fluorescence normalized as F/Fo. Control cultures (open symbols) were compared with cultures exposed to 500 µM amiloride at their apical surface (closed symbols). Measurements performed at 37 °C (three cultures/group ± S.E.). Single exponential fits are shown as solid lines. Bottom, summary of Pf values. Differences were not significant. B, plasma membrane osmotic water permeabilities of yellow fluorescent protein- and AQP-transfected FRT cells measured by calcein quenching. Top, representative time courses of calcein fluorescence in cultures of AQP3 (top curve)- and AQP4 (bottom curve)-transfected cells in response to hyperosmolar challenge and return to isosmolar solution, in the absence of amiloride. Bottom, summary of Pf (4-8 curves averaged from single cultures, three sets of cultures/condition ± S.E.). Differences were not significant.

 
As part of the present study, we characterized AQP expression and function in water transport across human bronchial epithelial cells. As discussed in the Introduction, a central prediction of the mechanism proposed by Donaldson et al. (1) is the inhibition of AQP water permeability by amiloride. To support their mechanism, the authors measured transepithelial flux across HBE cultures in response to an apically directed mannitol gradient, as we have done here (Fig. 2A), with two differences. First, in their study, the concentration of Texas Red-dextran was measured in the basolateral (rather than the apical) solution. Second, in their study, fluorescence was measured by confocal microscopy without any buffer sampling. They detected membrane transport rates as changes in cell height over time, with cytoplasmic calcein fluorescence imaged using reconstructed x-z confocal stacks. From both approaches, they reported a >70% reduction in osmotic water transport by 100-400 µM amiloride in non-CF and CF HBE cultures. Amiloride also prevented the transient increase in ASL volume upon acute addition of perfluorocarbon-dispersed NaCl to the mucosal surface of epithelial cultures, although this approach does not provide a direct measure of osmotic water permeability and was thus not replicated here. HgCl2, a toxic and non-specific inhibitor of AQPs, dramatically inhibited this ASL volume response, although this finding appears at odds with their prior report of a much milder (~30%) reduction of transepithelial and membrane water permeability by apically added HgCl2 (8). Based on these data, the authors proposed that inhibition of airway AQPs by amiloride accounted for the clinical effect and supported the hypothesis of ASL dehydration in CF.

Here, using essentially the same airway epithelial cell culture model used by Donaldson et al., we found no effect of amiloride on transepithelial or plasma membrane osmotic water permeability. Our fluorescence-based methods were capable of detecting small water permeability differences of <10%. Also, we found no effect of amiloride on the water permeability of individual airway/lung AQPs in transfected epithelial cells or in AQP5-dependent airspace-capillary water permeability in intact perfused mouse lung. We conclude that amiloride does not inhibit osmotically driven water transport in the airways or lung, indicating the need to identify other mechanism(s) to explain the paradoxical clinical observations reported by Donaldson et al. The discrepancy between our findings and those of Donaldson et al. may be related to differences in measurement techniques, as discussed above. The techniques of Donaldson et al. (1) were first employed by Matsui et al. (8) in characterizing HBE water permeabilities. This earlier study reported in both non-CF and CF P1 cultures a plasma membrane Pf (~90 µm/s) ~2-fold less than transepithelial Pf (~160 µm/s), which is a physical impossibility for a tight epithelium, because the apical and basolateral membranes are barriers in series. Here, our results for P0 cultures are very different, a higher membrane Pf (~200 µm/s), which is ~4-fold greater than transepithelial Pf (~50 µm/s). For non-CF and CF P1 cultures, we found a lower transepithelial Pf (~25 µm/s). Our results are consistent with the predicted lower transepithelial permeability of a multilayered cell culture.


Figure 6
View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 6.
Airspace-capillary water permeability in perfused mouse lung. A, representative traces of pleural surface fluorescein isothiocyanate-dextran fluorescence from wild-type mouse lung without (top, left) and with (top, right) 500 µM amiloride and from untreated lung of AQP5-null mouse (bottom). Pulmonary artery perfusate osmolality is indicated. B, summary of rates of capillary-airspace osmotic equilibration from experiments as described for A. (four mice/condition ± S.E.). Difference was not significant.

 
Without confirmed inhibition of AQP function, it remains difficult to understand the reported deleterious clinical effect of amiloride. Several small studies, including that by Donaldson et al. (1), have shown that amiloride does not reverse the HS-mediated acute increase in mucociliary clearance. For example, in 16 healthy subjects, a single dose of inhaled amiloride plus 7% HS did not increase or decrease mucociliary clearance compared with 7% HS alone (27). There is some evidence to suggest that inhaled amiloride alone, not paired with HS, may have a beneficial effect on mucociliary clearance in healthy and CF subjects (27, 28). However, it is reported that amiloride should not remain in lung tissue long enough to have significant long term effects on lung function (29). Amiloride is known to inhibit Na+/H+ exchange, so it is possible that the apparently negative effects of amiloride in the presence of a large hyperosmotic load are related to action at other site(s) on airway epithelial cells via alteration of cell pH regulation or ion balance.

Prior immunolocalization studies have reported the expression of AQP4 at the basolateral membrane surface in epithelial cells throughout large and small airways in mice, rats, and humans (reviewed in Ref. 30). AQP3 was found to have a more limited expression pattern in basolateral membranes in the basal cells of large and central airways and nasopharnyx. Several studies have shown the expression of AQP1 in microvascular endothelia through the airways/lung but not in epithelial cells (31, 32). AQP5 is expressed strongly in type I alveolar epithelial cells in humans and rodents and likely in some airway epithelial cells in human large airways (32, 33). In well differentiated primary cultures of human airway epithelial cells and in fixed human bronchi, we found here the expression of AQP3 and AQP4 in the basolateral membranes of airway epithelia but did not detect AQP5 protein expression. However, the lack of AQP5 immunostaining probably reflects a lack of antibody specificity rather than the absence of functional protein, given the demonstrated presence of AQP5 in nasal and bronchial epithelial cells in previous studies (33).

Prior functional studies have suggested the involvement of AQPs in airway water permeability. Our initial measurements in microperfused small airways from guinea pigs showed high transepithelial water permeability (Pf ~ 50 µm/s) that was weakly temperature-sensitive and was mercury-insensitive, suggesting the involvement of AQP4 (7). Recent data from spheroid explants of human nasal polyps provided evidence for AQP5 function in airway epithelia. In these large, spherical airway cell monolayers, with the ciliated apical membrane facing outward, Pederson et al. (9) reported high membrane Pf (~150 µm/s) that was sensitive to brief exposure to low concentration mercury. Here, our high Pf values for HBE cultures and the weak temperature dependence of permeability suggest AQP-mediated water movement (Fig. 2). Additionally, the reduced transepithelial osmotic water permeability under low pH in the basal (but not apical) membrane-facing solution provides indirect evidence for the function of AQP3 (the only pH-regulated airway AQP) in HBE basolateral membranes (19). The addition of HgCl2 to the cultures used here resulted in marked leakiness with reduced transepithelial resistance, precluding conclusions about HgCl2 effects. CF cultures had similar water permeability to non-CF cultures, consistent with our RT-PCR data (Fig. 3C) and with previous reports (8, 9).

On theoretical grounds the functioning of airway AQPs is not expected to be a significant determinant of ASL volume, composition, or other properties. Because the lipid bilayer in plasma membranes has substantial water permeability, the presence of AQPs generally increases plasma membrane water permeability by only 5-10-fold, which is important for rapid fluid movement, such as in kidney or salivary gland, but not for the many orders of magnitude slower fluid movement in the lung (reviewed in Ref. 34). Indeed, despite 10-fold slowed osmotic water permeability in mouse lung by the deletion of AQP1 and AQP5, isosmolar fluid absorption was unaffected (20, 35). Also, we reported previously that deletion of each of the airway/lung aquaporins (AQP1, AQP3, AQP4, and AQP5), individually and in combinations, did not affect ASL volume or ionic composition and had only a minimal effect of airway hydration at maximal respiratory rates (10).

The discussion above indicates the difficulty in ascribing aquaporin function, and increased ASL volume in general, to account for the effects of nebulized HS. Another potential problem with the hypothesis of increased ASL volume is that the excess fluid added to the intact airways/lung is likely to dissipate over minutes or tens of minutes rather than produce a sustained increased in ASL volume over hours between hypertonic saline treatments. Because of the large surface-to-volume ratio of the alveoli and airways and their high water permeability, added hypertonic fluid becomes nearly isotonic within 1 min due to osmotic water efflux into the airspaces. We showed rapid osmotic equilibration initially in sheep lung (36) and later in other mammals (18), including mouse as seen in Fig. 6. Because of rapid isosmolar fluid absorption in mammalian lung, including human lung (reviewed in Ref. 37), the ~40 ml of isosmolar fluid produced by nebulizing 5 ml of 7% HS is likely to be absorbed in <15-30 min. However, the exact clearance rate of HS would depend on its distribution in small versus large airways following nebulization. Rapid isosmolar fluid absorption has also been shown in the CF lung despite absent CFTR, because basal cAMP-independent lung fluid absorption does not involve CFTR (38). Thus, it is difficult to reconcile the clinical benefit of HS with the expected transient increase in ASL volume; however, the exact location of excess fluid, in terms of airways versus alveoli and periciliary versus mucus fluid, is not known. The increased ASL volume mechanism would also predict a better outcome for inhaling non-absorbed solutes, such as mannitol or xylitol, which from clinical studies is not the case (5).

Alternative mechanisms have been proposed to account for the apparent clinical benefit of inhaled hyperosmolar agents. One mechanism involves the direct effects of NaCl and mannitol on mucus rheology (5). HS has been proposed to reduce mucin entanglement by shielding fixed negative charges on the mucin backbone; mannitol has been proposed to compete with oligopolysaccharides on mucin macromolecules, thereby disrupting hydrogen bonds and reducing entanglements (39-41). A proposed mechanism for the benefit of mannitol is based on the hypothesis that a relatively salty ASL in CF decreases innate immune defenses, such as lysozyme, lactoferrin, and beta-defensins. If correct, a nonionic osmotic agent such as mannitol might be of benefit by reducing ASL salt concentration (5, 25, 42). Another proposed mechanism is the induction of cough in subjects inhaling hyperosmolar agents, which are quite irritating to the airways, although some studies conclude that changes in the mucociliary clearance are unlikely to be attributed to increased cough (3, 4, 22). Another proposed mechanism involves the direct or indirect action of hyperosmotic agents on mucus-secreting cells or sensory nerves in stimulating mucus secretion, whereby increased mucus secretion and ciliary action are proposed to "flush out" sticky, bacteria-laden secretions (5). We would add to this list the possibility of transient osmotic flow-induced convection of mucus into the airways as a major factor in the clinical benefit of HS. A critical re-examination of the mechanism(s) by which HS improves lung function in cystic fibrosis might lead to a better, mechanism-based approach for inhaled osmolar therapy.


   FOOTNOTES
 
* This work was supported by National Institutes of Health Grants HL59198, HL73856, DK35124, EB00415, and EY13574, Cystic Fibrosis Research and Translational Core Center Grant DK72517, and a Research Development Program grant from the Cystic Fibrosis Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 Supported by a National Institutes of Health Medical Scientist Training Grant. Back

2 To whom correspondence should be addressed: Cardiovascular Research Institute, 1246 Health Sciences E. Tower, University of California, San Francisco, CA 94143-0521. Tel.: 415-476-8530; Fax: 415-665-3847; E-mail: verkman{at}itsa.ucsf.edu.

3 The abbreviations used are: CF, cystic fibrosis; CFTR, CF transmembrane conductance regulator; ASL, airway surface liquid; AQP, aquaporin; FRT, Fisher rat thyroid; RT, reverse transcription; PBS, phosphate-buffered saline; HBE, human bronchial epithelial; MES, 4-morpholineethanesulfonic acid; HS, hypertonic saline; ENaC, epithelial sodium channel. Back


   ACKNOWLEDGMENTS
 
We thank Lorna Zlock and Jean Davidson for preparing cultures of human airway epithelia, Dr. Michael Matthay for assistance in the acquisition of lung specimens, Dr. Dan Zhao for help with RT-PCR analysis, Dr. Yaunlin Song for technical advice on mouse lung perfusion, and Liman Qian for mouse breeding and genotype analysis.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Donaldson, S. H., Bennett, W. D., Zeman, K. L., Knowles, M. R., Tarran, R., and Boucher, R. C. (2006) N. Engl. J. Med. 354, 241-250[Abstract/Free Full Text]
  2. Elkins, M. R., Robinson, M., Rose, B. R., Harbour, C., Moriarty, C. P., Marks, G. B., Belousova, E. G., Xuan, W., Bye, P. T., and the National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group (2006) N. Engl. J. Med. 354, 229-240[Abstract/Free Full Text]
  3. Robinson, M., Regnis, J. A., Bailey, D. L., King, M., Bautovich, G. J., and Bye, P. T. (1996) Am. J. Respir. Crit. Care Med. 153, 1503-1509[Abstract]
  4. Robinson, M., Hemming, A. L., Regnis, J. A., Wong, A. G., Bailey, D. L., Bautovich, G. J., King, M., and Bye, P. T. (1997) Thorax 52, 900-903[Abstract]
  5. Robinson, M., Daviskas, E., Eberl, S., Baker, J., Chan, H. K., Anderson, S. D., and Bye, P. T. (1999) Eur. Respir. J. 14, 678-685[Abstract]
  6. Eng, P. A., Morton, J., Douglass, J. A., Riedler, J., Wilson, J., and Robertson, C. F. (1996) Pediatr. Pulmonol. 21, 77-83[CrossRef][Medline] [Order article via Infotrieve]
  7. Folkesson, H., Matthay, M., Frigeri, A., and Verkman, A. S. (1996) J. Clin. Investig. 97, 664-671[Medline] [Order article via Infotrieve]
  8. Matsui, H., Davis, C. W., Tarran, R., and Boucher, R. C. (2000) J. Clin. Investig. 105, 1419-1427[Medline] [Order article via Infotrieve]
  9. Pedersen, P. S., Procida, K., Larsen, P. L., Holstein-Rathlou, N. H., and Frederiksen, O. (2005) Pfluegers Arch. 451, 464-473
  10. Song, Y., Jayaraman, S., Yang, B., Matthay, M. A., and Verkman, A. S. (2001) J. Gen. Physiol. 117, 573-582[Abstract/Free Full Text]
  11. Yamaya, M., Finkbeiner, W. E., Chun, S. Y., and Widdicombe, J. H. (1992) Am. J. Physiol. 262, L713-L724
  12. Fulcher, M. L., Gabriel, S., Burns, K. A., Yankaskas, J. R., and Randell, S. H. (2005) Methods Mol. Med. 107, 183-206[Medline] [Order article via Infotrieve]
  13. Pedemonte, N., Lukacs, G. L., Du, K., Caci, E., Zegarra-Moran, O., Galietta, L. J., and Verkman, A. S. (2005) J. Clin. Investig. 115, 2564-2571[CrossRef][Medline] [Order article via Infotrieve]
  14. Saadoun, S., Papadopoulos, M. C., Hara-Chikuma, M., and Verkman, A. S. (2005) Nature 434, 786-792[CrossRef][Medline] [Order article via Infotrieve]
  15. Solenov, E., Watanabe, H., Manley, G. T., and Verkman, A. S. (2004) Am. J. Physiol. 286, C426-C432
  16. Levin, M. H., and Verkman, A. S. (2004) Invest. Ophthalmol. Vis. Sci. 45, 4423-4432[Abstract/Free Full Text]
  17. Ma, T., Song, Y., Gillespie, A., Carlson, E. J., Epstein, C. J., and Verkman, A. S. (1999) J. Biol. Chem. 274, 20071-20074[Abstract/Free Full Text]
  18. Carter, E. P., Matthay, M. A., Farinas, J., and Verkman, A. S. (1996) J. Gen. Physiol. 108, 133-142[Abstract/Free Full Text]
  19. Zeuthen, T., and Klairke, D. A. (1999) J. Biol. Chem. 274, 21631-21636[Abstract/Free Full Text]
  20. Ma, T., Fukuda, N., Song, Y., Matthay, M. A., and Verkman, A. S. (2000) J. Clin. Investig. 105, 93-100[Medline] [Order article via Infotrieve]
  21. Daviskas, E., Anderson, S. D., Gonda, I., Eberl, S., Miekle, S., Seale, J. P., and Bautovich, G. (1996) Eur. Respir. J. 9, 725-732[Abstract]
  22. Pavia, D., Thomson, M. L., and Clarke, S. W. (1978) Am. Rev. Respir. Dis. 117, 199-203[Medline] [Order article via Infotrieve]
  23. Daviskas, E., Anderson, S. D., Brannan, J. D., Chan, H. K., Eberl, S., and Bautovich, G. (1997) Eur. Respir. J. 10, 2449-2454[Abstract]
  24. Daviskas, E., Anderson, S. D., Gomes, K., Briffa, P., Cochrane, B., Chan, H. K., Young, I. H., and Rubin, B. K. (2005) Respirology 10, 46-56[CrossRef][Medline] [Order article via Infotrieve]
  25. Zabner, J., Seiler, M. P., Launspach, J. L., Karp, P. H., Kearney, W. R., Look, D. C., Smith, J. J., and Welsh, M. J. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 11614-11619[Abstract/Free Full Text]
  26. Saijan, U., Moreira, J., Liu, M., Humar, A., Chaparro, C., Forstner, J., and Keshavjee, S. (2004) J. Heart Lung Transplant 23, 1382-1391[CrossRef][Medline] [Order article via Infotrieve]
  27. Sood, N., Bennett, W. D., Zeman, K., Brown, J., Foy, C., and Boucher R. C. (2003) Am. J. Respir. Crit. Care Med. 167, 158-163[Abstract/Free Full Text]
  28. App, E. M., King, M., Helfesrieder, R., Kohler, D., and Mattys, H. (1990) Am. Rev. Respir. Dis. 141, 605-612[Medline] [Order article via Infotrieve]
  29. Hirsch, A. J., Sabater, J. R., Zamurs, A., Smith, R. T., Paradiso, A. M., Hopkins, S., Abraham, W. M., and Boucher, R. C. (2004) J. Pharmacol. Exp. Ther. 311, 929-938[Abstract/Free Full Text]
  30. Borok, Z., and Verkman, A. S. (2002) J. Appl. Physiol. 93, 2199-2206[Abstract/Free Full Text]
  31. Hasegawa, H., Lian, S. C., Finkbeiner, W. E., and Verkman, A. S. (1994) Am. J. Physiol. 266, C893-C903
  32. Nielsen, S., King, L. S., Christensen, B. M., and Agre, P. (1997) Am. J. Physiol. 273, C1541-C1548
  33. Kreda, S. M., Gynn, M. C., Fenstermacher, D. A., Boucher, R. C., and Gabriel, S. E. (2001) Am. J. Respir. Cell Mol. Biol. 24, 224-234[Abstract/Free Full Text]
  34. Verkman, A. S. (2005) J. Cell Sci. 118, 3225-3232[Abstract/Free Full Text]
  35. Bai, C., Fukuda, N., Song, Y., Ma, T., Matthay, M. A., and Verkman, A. S. (1999) J. Clin. Investig. 103, 555-561[Medline] [Order article via Infotrieve]
  36. Folkesson, H. G., Matthay, M. A., Hasegawa, H., Kheradmand, F., and Verkman, A. S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4970-4974[Abstract/Free Full Text]
  37. Matthay, M. A., Folkesson, H., and Verkman, A. S. (1996) Am. J. Physiol. 270, L487-L503
  38. Fang, X., Fukuda, N., Barbry, P., Sartori, C., Verkman, A. S., and Matthay, M. A. (2002) J. Gen. Physiol. 119, 199-207[Abstract/Free Full Text]
  39. King, M., Dasgupta, B., Tomkiewicz, R. P., and Brown, N. E. (1997) Am. J. Respir. Crit. Care Med. 156, 173-177[Abstract/Free Full Text]
  40. Wills, P. J., Hall, R. L., Chan, W., and Cole, P. J. (1997) J. Clin. Investig. 99, 9-13[Medline] [Order article via Infotrieve]
  41. Feng, W., Garrett, H., Speert, D. P., and King, M. (1998) Am. J. Respir. Crit. Care Med. 157, 710-714[Abstract/Free Full Text]
  42. Durairaj, L., Launspach, J., Watt, J. L., Businga, T. R., Kline, J. N., Thorne, P. S., and Zabner, J. (2004) Respir. Res. 5, 13[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
A. J. Hirsh, J. Zhang, A. Zamurs, J. Fleegle, W. R. Thelin, R. A. Caldwell, J. R. Sabater, W. M. Abraham, M. Donowitz, B. Cha, et al.
Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 77 - 88.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/35/25803    most recent
M604332200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow